Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-19-003684
Filing Date
2019-05-01
Accepted
2019-05-01 08:01:19
Documents
64
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q sbbp-20190331x10q.htm 10-Q 1378561
2 EX-31.1 sbbp-20190331ex3110d421b.htm EX-31.1 17808
3 EX-31.2 sbbp-20190331ex312317b5b.htm EX-31.2 17764
4 EX-32.1 sbbp-20190331ex321379df8.htm EX-32.1 17610
  Complete submission text file 0001558370-19-003684.txt   5455657

Data Files

Seq Description Document Type Size
5 EX-101.INS sbbp-20190331.xml EX-101.INS 1132098
6 EX-101.SCH sbbp-20190331.xsd EX-101.SCH 43911
7 EX-101.CAL sbbp-20190331_cal.xml EX-101.CAL 48473
8 EX-101.DEF sbbp-20190331_def.xml EX-101.DEF 134116
9 EX-101.LAB sbbp-20190331_lab.xml EX-101.LAB 406300
10 EX-101.PRE sbbp-20190331_pre.xml EX-101.PRE 294528
Mailing Address 900 NORTHBROOK DRIVE, SUITE 200 TREVOSE PA 19053
Business Address 900 NORTHBROOK DRIVE, SUITE 200 TREVOSE PA 19053 (610) 254-9200
Strongbridge Biopharma plc (Filer) CIK: 0001634432 (see all company filings)

EIN.: 981130690 | State of Incorp.: L2
Type: 10-Q | Act: 34 | File No.: 001-37569 | Film No.: 19784855
SIC: 2834 Pharmaceutical Preparations